MetaVia Inc. presented preclinical data at ObesityWeek 2026 showing its dual-agonist DA-1726 achieved weight loss comparable to retatrutide in obese mice while requiring less food-intake suppression. The study highlighted DA-1726's ability to increase hepatic FGF21 expression and thermogenesis, supporting the company's plan to initiate a Phase 2 study in MetALD and ALD in the second half of 2027.
MetaVia's own release cites quantified preclinical head-to-head data: DA-1726 cut plasma glucose by 43.0%/39.2% vs 21.5%/32.5% for retatrutide and matched weight loss (41.7% vs 43.6%) with less food-intake suppression, plus higher hepatic FGF21. This supports the differentiated liver-focused profile and the planned Phase 2 in MetALD/ALD in H2 2027, but the data are from obese mice, not humans, so the price effect is limited. The Phase 1 figures (13.5% weight, 68.0% liver fat reduction) are restatements of earlier clinical data.
- ▲ Positive head-to-head preclinical data presented at ObesityWeek 2026 on November 14, 2026
- ▲ Phase 2 study in MetALD and ALD targeted to begin in the second half of 2027
- ▼ Data are preclinical (diet-induced obese mice) and may not translate to humans
- ▼ Phase 2 start is still roughly a year away, so no near-term clinical catalysts